ADARx Pharmaceuticals, Inc. insiders have been one-way buyers this past year: five people put roughly $87.7 million into the stock and nobody sold with their own money.
SR ONE CAPITAL MANAGEMENT, LLC (10% Owner) made the biggest buy, worth around $10.1 million.
Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Chimovits Erez | Director | Buy | 61,516 | $17.00 | $1.0M | SEC |
| Sep 30, 2026 | GORDON CARL L | Director | Buy | 300,249 | $17.00 | $5.1M | SEC |
| Sep 30, 2026 | GORDON CARL L | Director | Buy | 588,235 | $17.00 | $10.0M | SEC |
| Sep 30, 2026 | GORDON CARL L | Director | Buy | 61,516 | $17.00 | $1.0M | SEC |
| Sep 30, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 300,249 | $17.00 | $5.1M | SEC |
| Sep 30, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 61,516 | $17.00 | $1.0M | SEC |
| Sep 30, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 588,235 | $17.00 | $10.0M | SEC |
| Sep 29, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | 414,814 | $17.00 | $7.1M | SEC |
| Sep 29, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | 592,593 | $17.00 | $10.1M | SEC |
| Sep 29, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | 592,593 | $17.00 | $10.1M | SEC |
| Sep 29, 2026 | George Simeon | Director | Buy | 592,593 | $17.00 | $10.1M | SEC |
| Sep 29, 2026 | George Simeon | Director | Buy | 414,814 | $17.00 | $7.1M | SEC |
| Sep 29, 2026 | George Simeon | Director | Buy | 592,593 | $17.00 | $10.1M | SEC |
In the last 12 months ADARx Pharmaceuticals, Inc. insiders made open-market purchases worth about $87.7 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ADRX was filed on 2026-09-30.
No congressional trades in ADRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).